MA31086B1 - Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa. - Google Patents

Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.

Info

Publication number
MA31086B1
MA31086B1 MA32076A MA32076A MA31086B1 MA 31086 B1 MA31086 B1 MA 31086B1 MA 32076 A MA32076 A MA 32076A MA 32076 A MA32076 A MA 32076A MA 31086 B1 MA31086 B1 MA 31086B1
Authority
MA
Morocco
Prior art keywords
methods
inhibitor
factor
dosage formulations
unitary dosage
Prior art date
Application number
MA32076A
Other languages
English (en)
Inventor
Uma Sinha
Stanley J Hollenbach
Keith Abe
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39110529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31086(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA31086B1 publication Critical patent/MA31086B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE DES DOSES UNITAIRES DE COMPOSÉS INHIBITEURS DU FACTEUR XA ET DES PROCÉDÉS UTILISANT CES COMPOSÉS POUR INHIBER LA COAGULATION DU SANG CHEZ UN PATIENT HUMAIN. LA DOSE UNITAIRE DE COMPOSÉS INHIBITEURS DU FACTEUR XA DÉCRITE DANS LE PRÉSENT DOCUMENT NÉCESSAIRE POUR INHIBER LA COAGULATION CHEZ UN PRIMATE EST PLUS FAIBLE QUE LA DOSE UNITAIRE REQUISE POUR OBTENIR DES NIVEAUX SIMILAIRES D'INHIBITION DE LA COAGULATION CHEZ D'AUTRES MODÈLES D'ANIMAUX, TELS QUE LES RONGEURS. L'INVENTION CONCERNE ÉGALEMENT DES ESSAIS IN VITRO UTILES POUR PRÉDIRE L'ACTIVITÉ ANTI-THROMBOTIQUE IN VIVO CHEZ LES HUMAINS.
MA32076A 2006-12-08 2009-07-08 Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa. MA31086B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87379206P 2006-12-08 2006-12-08
US94762907P 2007-07-02 2007-07-02

Publications (1)

Publication Number Publication Date
MA31086B1 true MA31086B1 (fr) 2010-01-04

Family

ID=39110529

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32076A MA31086B1 (fr) 2006-12-08 2009-07-08 Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.

Country Status (18)

Country Link
US (1) US8404724B2 (fr)
EP (1) EP2101760B1 (fr)
KR (1) KR101472765B1 (fr)
CN (1) CN105193799A (fr)
AU (1) AU2007333377B2 (fr)
CA (2) CA2913963A1 (fr)
CO (1) CO6220933A2 (fr)
CR (1) CR10914A (fr)
EC (1) ECSP099501A (fr)
ES (1) ES2409090T3 (fr)
IL (1) IL199219A (fr)
MA (1) MA31086B1 (fr)
NI (1) NI200900145A (fr)
NZ (1) NZ578180A (fr)
PT (1) PT2101760E (fr)
RU (2) RU2452484C2 (fr)
SG (1) SG10201504425SA (fr)
WO (1) WO2008073670A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
CN101094867B (zh) 2004-10-19 2011-08-24 隆萨股份公司 用于固相肽合成的方法
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EA015942B1 (ru) * 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
PT2077995E (pt) * 2006-11-02 2012-05-10 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
EP2114930A2 (fr) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Inhibiteurs du facteur xa
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
NZ599556A (en) * 2007-05-02 2013-10-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
CA2758071C (fr) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Modulateurs de pyruvate kinase m2, compositions therapeutiques et methodes d'utilisation associees
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
WO2011084652A2 (fr) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Sels et formes cristallines d'inhibiteur de facteur xa
WO2011075602A1 (fr) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Procédés de préparation d'inhibiteurs du facteur xa et de leurs sels
US8394964B2 (en) 2009-12-17 2013-03-12 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor Xa inhibitors
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
CA2821975A1 (fr) 2010-12-17 2012-06-21 Shunqi Yan Derives de n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsufonamide comme modulateur de pyruvate kinase m2 pkm2
WO2012088314A1 (fr) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Activateurs bicycliques de pkm2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
JP6272754B2 (ja) 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
AU2012250690B2 (en) 2011-05-03 2017-06-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US20150224091A1 (en) * 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) * 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015010297A1 (fr) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
GB201322777D0 (en) * 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
WO2016205062A1 (fr) * 2015-06-15 2016-12-22 Shifa Biomedical Corporation Thérapies antithrombotiques
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
CA3069720A1 (fr) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides utilises en tant qu'inhibiteurs des canaux sodiques
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
EA032764B1 (ru) * 2018-01-19 2019-07-31 Общество С Ограниченной Ответственностью "Фармадиол" НОВЫЕ АМИДИНЫ - ИНГИБИТОРЫ ФАКТОРА Xa
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US12606797B2 (en) * 2018-06-15 2026-04-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of detection of mechanically-activated platelet activation and uses thereof
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
WO2020146682A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides utilisés en tant que modulateurs de canaux sodiques
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
JP2026506551A (ja) * 2023-02-02 2026-02-25 フロバイオ エルエルシー 薬物関連データ収集および解析のためのシステムおよび方法
WO2025264568A1 (fr) * 2024-06-20 2025-12-26 Flobio, Llc Système et procédé de collecte et d'analyse de données liées aux fonctions de coagulation et plaquettaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0813834B2 (ja) * 1990-08-01 1996-02-14 日東紡績株式会社 トリペプチド誘導体及びそれを有効成分とする蛋白分解酵素阻害剤
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
YU8395A (sh) * 1994-02-14 1998-07-10 Kirin Brewery Company Protein sa tpo aktivnošću
ATE272633T1 (de) * 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ES2254385T3 (es) * 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
GB0021497D0 (en) * 2000-09-01 2000-10-18 Novartis Res Foundation Compounds and their use
EP1322637A2 (fr) * 2000-09-29 2003-07-02 Millennium Pharmaceuticals, Inc. Inhibiteurs du facteur xa a base d'amidinos quaternaires
RU2440986C2 (ru) * 2005-11-08 2012-01-27 Милленниум Фамэсьютикэлс, Инк. СОЛЬ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОСТОЯЩИЕ ИЗ НАЗВАННОЙ КОМПОЗИЦИИ ТАБЛЕТКА, КАПСУЛА И ЛЕПЕШКА, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ

Also Published As

Publication number Publication date
CA2671502A1 (fr) 2008-06-19
PT2101760E (pt) 2013-05-07
ECSP099501A (es) 2010-01-29
CO6220933A2 (es) 2010-11-19
NZ578180A (en) 2012-02-24
CN105193799A (zh) 2015-12-30
WO2008073670A2 (fr) 2008-06-19
RU2452484C2 (ru) 2012-06-10
CA2671502C (fr) 2017-01-24
SG10201504425SA (en) 2015-07-30
IL199219A (en) 2013-10-31
RU2009126147A (ru) 2011-01-20
AU2007333377A1 (en) 2008-06-19
AU2007333377B2 (en) 2014-01-16
WO2008073670A3 (fr) 2008-11-27
ES2409090T3 (es) 2013-06-24
HK1134031A1 (en) 2010-04-16
RU2012104816A (ru) 2013-08-20
EP2101760B1 (fr) 2013-02-27
US8404724B2 (en) 2013-03-26
US20080153876A1 (en) 2008-06-26
IL199219A0 (en) 2010-03-28
CR10914A (es) 2009-08-12
CA2913963A1 (fr) 2008-06-19
KR101472765B1 (ko) 2014-12-15
EP2101760A2 (fr) 2009-09-23
KR20090107499A (ko) 2009-10-13
NI200900145A (es) 2010-11-29

Similar Documents

Publication Publication Date Title
WO2008073670A3 (fr) Formulations de doses unitaires et procédés de traitement d'une thrombose avec un inhibiteur oral du facteur xa
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200802213A1 (ru) Способы лечения заболеваний крови
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
MA29326B1 (fr) Combinaison de composes organiques
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
WO2004014844A3 (fr) Composes aryle et heteroaryle et procedes de modulation de la coagulation
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
EP2103312A4 (fr) Préparation pour la stérilisation ou la désinfection d'un tissu
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
NO20076405L (no) Anvendelse av 24-nor-UDCA
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
DE60237248D1 (de) Neues molekulares Target der Neurotoxizität
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
EP2382206A4 (fr) Composés et procédés pour le traitement de la douleur et d'autres maladies
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций